Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EMBC
EMBC logo

EMBC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Embecta Corp (EMBC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
8.570
1 Day change
-3.38%
52 Week Range
15.550
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Embecta Corp (EMBC) does not present a compelling buy opportunity at this time for a beginner, long-term investor. The technical indicators are bearish, options sentiment is neutral to slightly bearish, and the company's financial performance shows stagnation in growth metrics. Without any significant positive catalysts or strong trading signals, it is advisable to hold off on investing in this stock.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 36.428, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its support level (S1: 8.718), with resistance levels at R1: 9.325 and R2: 9.513. Overall, the trend is bearish.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The open interest put-call ratio and option volume put-call ratio suggest neutral to slightly bearish sentiment. Implied volatility is moderately high at 66.72%, with an IV percentile of 65.34, indicating the stock is relatively volatile compared to its historical range.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
2

Positive Catalysts

  • NULL identified. There are no recent news events, significant insider or hedge fund activity, or congress trading data to suggest a positive catalyst.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of growth in financial performance, and no significant trading trends from insiders or hedge funds.

Financial Performance

In Q1 2026, revenue dropped slightly by -0.27% YoY to $261.2M. Net income and EPS remained flat YoY at $44.1M and $0.74, respectively. Gross margin declined by -4.42% YoY to 60.91%, indicating potential cost pressures or inefficiencies.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available for EMBC.

Wall Street analysts forecast EMBC stock price to rise
Analyst Rating
0
Wall Street analysts forecast EMBC stock price to rise
Buy
Hold
Sell
0
Current: 8.870
sliders
Low
0
Averages
0
High
0
0
Current: 8.870
sliders
Low
0
Averages
0
High
0
BofA
BofA
Underperform
downgrade
$18 -> $11
AI Analysis
2025-08-08
Reason
BofA
BofA
Price Target
$18 -> $11
AI Analysis
2025-08-08
downgrade
Underperform
Reason
BofA lowered the firm's price target on Embecta to $11 from $18 and keeps an Underperform rating on the shares. The firm notes the company's Q3 revenue of $296M was $17M better than Street's $278M driven by ordering timing benefit from distribution stocking ahead of July 4th holiday, incremental stocking related to brand transition and $7M favorable pricing driven by year-to-date rebate reserve adjustments in the U.S. In Q4, Embecta expects revenues to step down to $265M as order timing benefit reverses, FX to be a $3M incremental h/w and China revenues decline quarter-over-quarter. BofA remains bearish on the stock as it does not see much revenue growth.
Mizuho
Neutral
downgrade
$13 -> $12
2025-07-16
Reason
Mizuho
Price Target
$13 -> $12
2025-07-16
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on Embecta to $12 from $13 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for EMBC
Unlock Now

People Also Watch